XTX Topco Ltd Invests $82,000 in Exscientia plc (NASDAQ:EXAI)

XTX Topco Ltd acquired a new stake in shares of Exscientia plc (NASDAQ:EXAI) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 16,858 shares of the company’s stock, valued at approximately $82,000.

Other hedge funds also recently bought and sold shares of the company. Novo Holdings A S bought a new position in Exscientia in the 2nd quarter worth about $66,742,000. Bank of New York Mellon Corp grew its stake in Exscientia by 108.8% in the second quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock worth $1,981,000 after purchasing an additional 202,377 shares in the last quarter. Jane Street Group LLC increased its holdings in Exscientia by 601.7% during the 3rd quarter. Jane Street Group LLC now owns 290,154 shares of the company’s stock worth $1,416,000 after purchasing an additional 248,805 shares during the period. Olympiad Research LP purchased a new position in Exscientia during the 3rd quarter worth $448,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Exscientia in the 2nd quarter worth $256,000. Institutional investors own 41.58% of the company’s stock.

Exscientia Price Performance

EXAI opened at $4.84 on Friday. The company has a current ratio of 4.54, a quick ratio of 4.54 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $5.00 and its 200-day simple moving average is $5.13. The company has a market capitalization of $632.93 million, a price-to-earnings ratio of -3.21 and a beta of 0.83. Exscientia plc has a 12-month low of $3.80 and a 12-month high of $7.91.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.